--- title: "Real-Time PMA Supplement Review, Definition | MedTech Terms" description: "Expedited PMA supplement review pathway where FDA and the manufacturer meet to review minor device or labeling changes in real time." lang: en json-ld: | { "@context": "https://schema.org", "@graph": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/pma-real-time-review#term", "name": "Real-Time PMA Supplement Review", "alternateName": [ "Real-Time Review", "RTR PMA Supplement" ], "description": "Real-Time Review is an FDA option for minor PMA supplements where the agency and the manufacturer schedule a face-to-face or virtual meeting to review the proposed change together, with the goal of issuing a decision at or shortly after the meeting. It is appropriate for minor changes to design, software, manufacturing, sterilization, or labeling that do not affect safety or effectiveness. Sponsors must submit eligible-determination requests in advance, and FDA must agree that the change qualifies before scheduling.", "url": "https://medtechterms.com/terms/pma-real-time-review", "termCode": "pma-real-time-review", "inDefinedTermSet": { "@type": "DefinedTermSet", "name": "MedTech Terms", "url": "https://medtechterms.com/terms" } }, { "@type": "Article", "@id": "https://medtechterms.com/terms/pma-real-time-review#article", "headline": "Real-Time PMA Supplement Review", "description": "Expedited PMA supplement review pathway where FDA and the manufacturer meet to review minor device or labeling changes in real time.", "url": "https://medtechterms.com/terms/pma-real-time-review", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://medtechterms.com/terms/pma-real-time-review" }, "about": { "@id": "https://medtechterms.com/terms/pma-real-time-review#term" }, "articleSection": "Regulatory", "inLanguage": "en", "keywords": "Real-Time PMA Supplement Review, Real-Time Review, RTR PMA Supplement, Regulatory, medical device, MedTech", "author": { "@type": "Person", "name": "Christian Espinosa", "jobTitle": "Founder, Blue Goat Cyber", "url": "https://bluegoatcyber.com" }, "publisher": { "@type": "Organization", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "isPartOf": { "@type": "WebSite", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "datePublished": "2026-06-20", "dateModified": "2026-06-20", "citation": [ { "@type": "CreativeWork", "name": "Real-Time PMA Supplements Guidance", "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-time-premarket-approval-application-supplements", "publisher": { "@type": "Organization", "name": "FDA" } }, { "@type": "CreativeWork", "name": "IMDRF Documents", "url": "https://www.imdrf.org/documents", "publisher": { "@type": "Organization", "name": "IMDRF" } }, { "@type": "CreativeWork", "name": "RAPS Regulatory Focus", "url": "https://www.raps.org/news-and-articles/news-articles", "publisher": { "@type": "Organization", "name": "RAPS" } } ], "mentions": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/pma#term", "name": "Premarket Approval", "alternateName": "PMA", "url": "https://medtechterms.com/terms/pma" }, { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/pma-modular#term", "name": "Modular PMA", "url": "https://medtechterms.com/terms/pma-modular" }, { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/pma-supplement-types#term", "name": "PMA Supplement Types", "url": "https://medtechterms.com/terms/pma-supplement-types" }, { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/annual-report-pma#term", "name": "Annual Report (PMA)", "url": "https://medtechterms.com/terms/annual-report-pma" }, { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/ai-ml-pccp#term", "name": "Predetermined Change Control Plan", "alternateName": "PCCP", "url": "https://medtechterms.com/terms/ai-ml-pccp" } ] }, { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://medtechterms.com/" }, { "@type": "ListItem", "position": 2, "name": "Terms", "item": "https://medtechterms.com/terms" }, { "@type": "ListItem", "position": 3, "name": "Regulatory", "item": "https://medtechterms.com/terms?cat=Regulatory" }, { "@type": "ListItem", "position": 4, "name": "Real-Time PMA Supplement Review", "item": "https://medtechterms.com/terms/pma-real-time-review" } ] } ] } --- [ MedTech Terms The authoritative reference ](/) Browse Learn [Latest](/latest) About 1. [Home](/) 2. / 3. [Terms](/terms) 4. / 5. [Regulatory](/terms?cat=Regulatory) 6. / 7. Real-Time PMA Supplement Review [All terms](/terms) Regulatory [Regulated Pathways](/ecosystems/regulated-pathways)[Global Markets](/ecosystems/global-markets) # Real-Time PMA Supplement Review Expedited PMA supplement review pathway where FDA and the manufacturer meet to review minor device or labeling changes in real time. Reviewed by [Christian Espinosa, Founder, Blue Goat Cyber](/authors/christian-espinosa) Last reviewed June 20, 2026 ## Definition Real-Time Review is an FDA option for minor [PMA](/terms/pma) supplements where the agency and the manufacturer schedule a face-to-face or virtual meeting to review the proposed change together, with the goal of issuing a decision at or shortly after the meeting. It is appropriate for minor changes to design, software, manufacturing, [sterilization](/terms/sterilization), or [labeling](/terms/labeling) that do not affect safety or effectiveness. Sponsors must submit eligible-determination requests in advance, and FDA must agree that the change qualifies before scheduling. What the regulation says FDA's 'Real-Time [Premarket Approval](/terms/pma) Application Supplements' guidance defines eligibility and procedural expectations. Real-Time Review is one of several supplement pathways alongside Special PMA Supplement (changes to manufacturing), 30-Day Notice (manufacturing changes meeting specific criteria), and traditional PMA Supplement. ## What this means in practice Real-Time Review can dramatically shorten the supplement timeline (often weeks instead of months) when used for genuinely minor changes. It is widely used for low-risk software changes, minor label updates, and incremental manufacturing process changes. For software-containing devices, RTR is a common path for changes that fall outside a [Predetermined Change Control Plan](/terms/ai-ml-pccp) but are still narrow in scope. Common pitfalls - • Requesting Real-Time Review for changes that aren't truly minor, FDA will reject the request and the sponsor loses time. - • Failing to prepare materials at PMA-supplement quality for the meeting, Real-Time Review compresses calendar time, not depth of evidence. - • Conflating Real-Time Review with the Special PMA Supplement (manufacturing-change-in-effect) pathway, they apply to different change types. ## Related terms Grouped by theme ### Editor's picks · Hand-selected related concepts [ Regulatory Modular PMA PMA submission strategy where a manufacturer submits portions of the PMA (modules) sequentially as they become ready, rather than as a single complete application. ](/terms/pma-modular)[ Regulatory PMA Supplement Types FDA's five-way taxonomy for post-approval PMA changes, Panel-Track, 180-Day, Real-Time, Special, and 30-Day Notice, each with distinct content and timing. ](/terms/pma-supplement-types)[ Regulatory Premarket Approval(PMA) FDA's most stringent device marketing application, required for high-risk Class III devices. ](/terms/pma)[ Post-Market Annual Report (PMA) Yearly report required for Class III PMA devices summarizing changes, complaints, and post-approval study status. ](/terms/annual-report-pma) ### More in Regulatory · Same category [ Regulatory 510(k) Premarket Notification(510(k)) FDA submission demonstrating a device is substantially equivalent to a legally marketed predicate. ](/terms/510k)[ Regulatory 510(k) Summary vs 510(k) Statement Two alternative disclosure mechanisms in a 510(k) submission, a Summary is public on FDA's website; a Statement promises to share Safety & Effectiveness info on request. ](/terms/510k-summary-vs-statement)[ Regulatory 513(g) Request for Information(513(g)) Formal mechanism to ask FDA whether a product is a device and, if so, its likely classification. ](/terms/513g)[ Regulatory Abbreviated 510(k) 510(k) variant that relies on FDA guidance, special controls, or recognized consensus standards. ](/terms/abbreviated-510k) Cited by Where this term appears across MedTech Terms. Ecosystems (2) - [Regulated Pathways](/ecosystems/regulated-pathways) - [Global Markets](/ecosystems/global-markets) ## Primary references 3 sources Link health: 3 verified · last checked 2026-06-20 FDA· 1 IMDRF· 1 RAPS· 1 1. [1 Real-Time PMA Supplements Guidance Verified FDA · fda.gov ](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-time-premarket-approval-application-supplements) 2. [2 IMDRF Documents Verified IMDRF · imdrf.org ](https://www.imdrf.org/documents) 3. [3 RAPS Regulatory Focus Verified RAPS · raps.org ](https://www.raps.org/news-and-articles/news-articles) Inline markers like \[1\] jump to the matching reference above. Sponsor note ### Navigating an FDA or EU MDR submission? Blue Goat Cyber supports the cybersecurity content of premarket submissions, from threat models to the 524B narrative. [Book a 30-minute discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) - No obligation - Expert-led from minute one - NDA available on request MedTech Terms is a community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com). Definitions are independent of any vendor. On this term Category Regulatory Sources 3 Updated 6/20/2026 [Compare with another term](/compare?a=pma-real-time-review) Learn in 60 seconds Card Lesson Quiz Expedited PMA supplement review pathway where FDA and the manufacturer meet to review minor device or labeling changes in real time. - · Real-Time Review can dramatically shorten the supplement timeline (often weeks instead of months) when used for genuinely minor changes. - · It is widely used for low-risk software changes, minor label updates, and incremental manufacturing process changes. - · For software-containing devices, RTR is a common path for changes that fall outside a Predetermined Change Control Plan but are still narrow in scope. Remember this Watch out: Requesting Real-Time Review for changes that aren't truly minor, FDA will reject the request and the sponsor loses time. Related terms - [Premarket Approval(PMA) ](/terms/pma) - [Modular PMA ](/terms/pma-modular) - [PMA Supplement Types ](/terms/pma-supplement-types) - [Annual Report (PMA) ](/terms/annual-report-pma) - [Predetermined Change Control Plan(PCCP) ](/terms/ai-ml-pccp) You may also need Auto-suggested from Regulatory and shared keywords. - [Change Control ](/terms/change-control) - [510(k) Summary vs 510(k) Statement ](/terms/510k-summary-vs-statement) - [Letter to File(LTF) ](/terms/letter-to-file) - [Special 510(k)(Special 510(k)) ](/terms/special-510k) - [General Safety and Performance Requirements (IVDR)(GSPR) ](/terms/ivdr-gspr) - [Substantial Equivalence(SE) ](/terms/substantial-equivalence) [All Regulatory terms](/terms?cat=Regulatory) From the Blue Goat network Related resources and services on this topic. - [ MedTech Cybersecurity Standards Authoritative reference for the standards and guidances behind medical device cybersecurity. ](https://medtechcyberstandards.com) - [ MedTech Cybersecurity Crosswalk International crosswalk of medical device cybersecurity requirements across regulators. ](https://mdccrosswalk.com) - [ MedTech Truths Common misconceptions about medical device development - debunked. ](https://mdcmisconceptions.com) - [ MedTech Launchpad MedTech funding rounds, accelerators, and launch resources. ](https://medtechlaunchguide.com) MedTech Terms An authoritative, plain-language reference for the regulatory, quality, cybersecurity, and software terms that shape modern medical devices. Browse - [All terms](/terms) - [A–Z index](/a-z) - [Categories](/categories) - [Ecosystems](/ecosystems) - [Learning paths](/paths) - [Compare terms](/compare) - [Quiz](/quiz) Resources - [FDA Medical Devices](https://www.fda.gov/medical-devices) - [EU MDR](https://eur-lex.europa.eu/eli/reg/2017/745/oj) - [IMDRF](https://www.imdrf.org/) - [Methodology](/methodology) - [Changelog](/changelog) - [Editor: Christian Espinosa](/authors/christian-espinosa) - [About this site](/about) © 2026 MedTech Terms. Reference content for educational purposes - not regulatory advice. A community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com)